Can-Fite says Phase III namodenoson trial in advanced liver cancer advances under FDA, EMA guidance
Reuters2026/08/12 11:08Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
- Can-Fite highlighted late-stage progress for two oral drug candidates, with pivotal Phase III programs underway for liver cancer and plaque psoriasis.
- No clinical results were reported; the liver cancer study is positioned to support future US and European filings if endpoints are met.
- Namodenoson is being tested in advanced hepatocellular carcinoma patients with Child-Pugh B7 cirrhosis under FDA and EMA regulatory guidance.
- Regulatory positioning includes FDA Fast Track for Namodenoson, with Orphan Drug designations in the US and Europe.
- Piclidenoson remains in Phase III development in moderate-to-severe plaque psoriasis, reinforcing the company’s late-stage pipeline focus.
Disclaimer:
This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Can Fite Biofpharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608120700PRIMZONEFULLFEED9808554) on August 12, 2026, and is solely responsible for the information contained therein.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!
You may also like
Canadian Dollar eases from highs as risk aversion buoys the US Dollar
FXStreet•2026/09/08 11:54
XRP Avengers claims holding 10,000 XRP could yield $1 million, community reacts
Cointurk•2026/09/08 11:51
Genmab shareholders to vote on unchanged 2026 board pay plan at Oct. 7 EGM
Reuters•2026/09/08 11:48
Crypto prices
MoreBitcoin
BTC
$78,392.79
-1.28%
Ethereum
ETH
$2,473.35
-0.68%
Tether USDt
USDT
$0.9996
-0.03%
BNB
BNB
$751.52
+1.03%
XRP
XRP
$1.39
-0.48%
USDC
USDC
$0.9999
+0.00%
Solana
SOL
$102.78
-1.98%
TRON
TRX
$0.3384
+0.59%
Hyperliquid
HYPE
$83.05
-5.24%
Zcash
ZEC
$1,155.89
-3.20%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now